10x Genomics (TXG) Debt Ratio (2018 - 2019)
10x Genomics (TXG) reported Debt Ratio of 0.05 for Q4 2019, down 79.45% on a YoY basis from 0.24 in Q4 2018, and down 5.37% sequentially from 0.05 in Q3 2019.
10x Genomics (TXG) Debt Ratio (2018 - 2019) Analysis & Trends
10x Genomics (TXG) has 2 years of Debt Ratio data on file, last reported at 0.05 in Q4 2019.
- For the quarter ending Q4 2019, Debt Ratio fell 79.45% year-over-year to 0.05; the trailing twelve-month figure through Dec 2019 stood at 0.05 (down 79.45% YoY), and the FY2019 full-year result was 0.05, down 79.45% from the prior year.
- Debt Ratio declined to 0.05 in Q4 2019, from 0.05 in the prior quarter.
- In the past five years, Debt Ratio ranged from a high of 0.24 in Q4 2018 to a low of 0.05 in Q4 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Veeva Systems | 29.34 Bn | 22.03 Bn | 662.02 Mn | - |
| 2 | BrightSpring Health Services | 13.49 Bn | 12.59 Bn | 482.22 Mn | 0.40 |
| 3 | Healthequity | 7.96 Bn | 7.70 Bn | 256.31 Mn | 0.29 |
| 4 | 10x Genomics | 6.17 Bn | 5.63 Bn | 106.18 Mn | - |
| 5 | Hinge Health | 6.02 Bn | 5.70 Bn | 154.23 Mn | - |
| 6 | MiniMed | 4.19 Bn | 3.89 Bn | 480.00 Mn | - |
| 7 | Waystar Holding | 4.14 Bn | 4.07 Bn | 216.84 Mn | 0.25 |
| 8 | Doximity | 3.82 Bn | 3.08 Bn | 125.97 Mn | - |
| 9 | Privia Health | 3.10 Bn | 2.73 Bn | - | - |
| 10 | Omnicell | 1.81 Bn | 1.57 Bn | 140.36 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | 0.05 |
| Sep 30, 2019 | 0.05 |
| Dec 31, 2018 | 0.24 |